Trial Profile
A Phase 2, Open-label, Single-arm Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Leukaemia; Mesothelioma; Multiple myeloma; Solid tumours; Testicular cancer
- Focus Therapeutic Use
- Sponsors Seagen
- 16 Apr 2019 Protocol was amended to allow dosing at 2.4 mg/kg Q3W in patients with solid tumors as per the results published in the Investigational New Drugs.
- 16 Apr 2019 Results published in the Investigational New Drugs
- 20 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.